Quorum Innovations
Quorum Innovations is a biopharmaceutical company focused on discovering, developing, and delivering innovative microbiome therapeutics. They aim to become a leader in the emerging field of microbiome therapeutics by leveraging their proprietary platforms and understanding of the human microbiome's pivotal role in health and disease.
Industries
Nr. of Employees
small (1-50)
Quorum Innovations
2068 Hawthorne Street, Sarasota, FL 34236
Patents
Materials and methods for improving immune responses and skin and/or mucosal barrier functions
US-12440521-B2
View DetailsMaterials and methods for inhibiting a viral infection, including a coronavirus infection
US-11826390-B2
View Details
Materials and methods for improving immune responses and skin and/or mucosal barrier functions
US-12440521-B2
View DetailsMaterials and methods for inhibiting a viral infection, including a coronavirus infection
US-11826390-B2
View DetailsProducts
Topical skin health products derived from human microbiome bioactives
Consumer-facing topical formulations containing processed bioactive extracts sourced from human microbiota, intended to modulate skin microbiome ecology and promote barrier proteins.
Topical skin health products derived from human microbiome bioactives
Consumer-facing topical formulations containing processed bioactive extracts sourced from human microbiota, intended to modulate skin microbiome ecology and promote barrier proteins.
Services
Collaboration and joint development opportunities to advance preclinical data packages and move candidates toward clinical milestones; contact via company partnership channel.
Collaboration and joint development opportunities to advance preclinical data packages and move candidates toward clinical milestones; contact via company partnership channel.
Expertise Areas
- Microbiome therapeutics discovery
- Translational medicine (clinically driven discovery)
- Dermatological and mucosal therapeutic development
- Anti-biofilm therapeutics
Key Technologies
- Biofilm-based extraction of microbial bioactives
- Human-derived probiotic strain isolation
- In vitro biofilm adhesion and detachment assays
- Ex vivo and in vitro inflammatory marker assays (e.g., IL-1a)
News & Updates
Dr. Nicholas Monsul, Chairman/Founder of Quorum Innovations, delivered a key address at the Microbiome Summit in Vienna, demonstrating capabilities to modulate the skin microbiota and restore microbiome ecology by stimulating the innate immune response.
Quorum Innovations demonstrated the modulation of the human microbiome, showcasing their advancements in microbiome therapeutics.
Quorum Innovations was recognized in a report by Silicon Valley Bank on investment trends in the microbiome space.
The USPTO granted a patent allowance for Quorum's methods and compositions for treating dermatological conditions by employing a microbiome-centered approach.
Quorum announced the availability of microbiome therapeutics for skin conditions and metabolic disorders, emphasizing their proprietary bioactive compounds derived from the human microbiome.
Dr. Nicholas Monsul discussed how Quorum has developed a drug platform that modulates the skin microbiome by increasing beneficial bacteria and inhibiting pathogens like MRSA.
Dr. Nicholas Monsul, Chairman/Founder of Quorum Innovations, delivered a key address at the Microbiome Summit in Vienna, demonstrating capabilities to modulate the skin microbiota and restore microbiome ecology by stimulating the innate immune response.
Quorum Innovations demonstrated the modulation of the human microbiome, showcasing their advancements in microbiome therapeutics.
Quorum Innovations was recognized in a report by Silicon Valley Bank on investment trends in the microbiome space.
The USPTO granted a patent allowance for Quorum's methods and compositions for treating dermatological conditions by employing a microbiome-centered approach.
Quorum announced the availability of microbiome therapeutics for skin conditions and metabolic disorders, emphasizing their proprietary bioactive compounds derived from the human microbiome.
Dr. Nicholas Monsul discussed how Quorum has developed a drug platform that modulates the skin microbiome by increasing beneficial bacteria and inhibiting pathogens like MRSA.